Abstract | AIMS: METHODS AND RESULTS: We conducted a systematic literature search to identify all randomized controlled trials comparing sirolimus or paclitaxel-eluting stents with bare metal stents and reporting mortality data after at least 1 year of follow-up. Trial data were reviewed and extracted independently by two investigators in an unblinded standardized manner. Seventeen trials including a total of 8221 patients were analysed. Peto's odds ratios ( ORs) for total mortality after 1 (n=8221), 2 (n=4631), 3 (n=4105), and 4 (n=1293) years of follow-up were 0.94 [95% confidence interval (CI) 0.66-1.34], 1.11 (95% CI 0.76-1.61), 1.25 (95% CI 0.91-1.73), and 1.46 (95% CI 0.92-2.31), respectively. Corresponding ORs for non-cardiac mortality were 1.07 (95% CI 0.64-1.80), 1.72 (95% CI 1.01-2.94), 1.45 (95% CI 0.93-2.25), and 1.65 (95% CI 0.89-3.10). There was no difference in OR for cardiac mortality among all trials. In sensitivity analyses, sirolimus- but not paclitaxel-eluting stents were associated with an increase in non-cardiac mortality at 2 and 3 years of follow-up. CONCLUSION:
|
Authors | Alain Joel Nordmann, Matthias Briel, Heiner Claudins Bucher |
Journal | European heart journal
(Eur Heart J)
Vol. 27
Issue 23
Pg. 2784-814
(Dec 2006)
ISSN: 0195-668X [Print] England |
PMID | 17020889
(Publication Type: Comparative Study, Evaluation Study, Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Drug Implants
- Immunosuppressive Agents
- Tubulin Modulators
- Paclitaxel
- Sirolimus
|
Topics |
- Aged
- Coronary Artery Disease
(mortality, therapy)
- Drug Implants
- Follow-Up Studies
- Graft Occlusion, Vascular
(etiology)
- Humans
- Immunosuppressive Agents
(administration & dosage)
- Middle Aged
- Paclitaxel
(administration & dosage)
- Randomized Controlled Trials as Topic
- Sensitivity and Specificity
- Sirolimus
(administration & dosage)
- Stents
- Tubulin Modulators
(administration & dosage)
|